Assistant Professor, Fuzhou University, Pakistan
Majid Khan, Ph.D., is an accomplished biochemist from Pakistan with extensive experience in drug development. He specializes in both in-vitro and in-vivo drug testing phases, demonstrating expertise in delivering high-quality results. Khan is proficient in refining testing protocols and optimizing development processes, ensuring rigorous and accurate outcomes. His leadership, communication, and teamwork skills have earned him a reputation for mentoring and guiding new team members in a collaborative environment. Khan’s dedication to scientific research and his ability to simplify complex ideas for non-technical audiences have set him apart as a respected figure in his field. 🌟🧬
Publication Profile
Google Scholar
Education:
Majid Khan holds a Ph.D. in Biochemistry from the H.E.J. Research Institute of Chemistry, University of Karachi (2018-2021), where he investigated inhibitors of ureases. He completed his M.Phil. in Biochemistry (2014-2017) at the same institute, focusing on the effects of urease inhibitors on urolithiasis-causing bacteria. His academic journey began with a BS (Hons) in Biochemistry from Hazara University (2008-2012) and was preceded by pre-medical studies at Govt Post-Graduate College, Charssada. 🎓📚
Experience:
Dr. Khan’s expertise spans across drug development, specifically focusing on the mechanism of action of various enzyme inhibitors. His work in biochemistry has not only involved cutting-edge research but also practical applications in addressing major health issues, such as urolithiasis, diabetes, and cancer. Khan’s contributions to both academic and industrial sectors showcase his proficiency in lab-based and computational research. His role in scientific communities, guiding young researchers, and his collaborations with other professionals have been key to his successful career. 🔬💼
Awards and Honors:
Dr. Khan’s outstanding contributions to biochemistry and drug development have been recognized through various accolades and citations. His research publications have garnered significant attention, with a high h-index of 11 and over 340 citations. Khan’s work continues to contribute meaningfully to the field, and his expertise is acknowledged globally. 🏅🎖
Research Focus:
Dr. Khan’s research primarily involves the discovery and mechanistic study of enzyme inhibitors, with a focus on urease inhibitors and their therapeutic potential. His ongoing work explores compounds that show promise in treating conditions such as diabetes, cancer, and peptic ulcers. His studies also emphasize the in-silico and biochemical screening of natural and synthetic compounds to combat these diseases, highlighting his commitment to developing novel drug therapies. 🔬💊
Conclusion:
Dr. Majid Khan’s extensive academic background, combined with his diverse experience in drug development and biochemical research, places him at the forefront of biochemistry and pharmacology. His work, which bridges the gap between basic and applied research, continues to advance the understanding of disease mechanisms and drug efficacy. With a passion for teaching and mentoring, he plays a significant role in shaping the next generation of scientists. 👨🔬🌱
Publications:
Majid Khan, Sobia Ahsan Halim, Najeeb Ur Rehman, et al. “Cytotoxic natural products from Aloe vera resin inhibit carbonic anhydrases-II and -IX” (Accepted in International Journal of Biological Macromolecules, IF: 8.2)
Majid Khan, Atta Ullah, Sobia Ahsan Halim, et al. “Exploring Tryptamine Derivatives as Potential Agents for Diabetes and Cancer Treatment” (Accepted in International Journal of Biological Macromolecules, IF: 8.2)
Majid Khan, Arsalan Nizamani, et al. “Utilizing the drug repurposing strategy on current drugs” (Journal of Biomolecular Structure and Dynamics, 2024, IF: 5.235)
Majid Khan, Sobia Ahsan Halim, et al. “Isoxazole analogues of dibenzazepine as possible leads against ulcers and skin disease” (Saudi Pharmaceutical Journal, 2023, IF: 4.562)
Majid Khan, Sobia Ahsan Halim, et al. “Substrate-like novel inhibitors of prolyl specific oligopeptidase for neurodegenerative disorders” (Journal of Biomolecular Structure and Dynamics, 2023, IF: 5.235)
Majid Khan, Satya Kumar Avula, et al. “Biochemical and in silico inhibition of bovine and human carbonic anhydrase-II by 1H-1,2,3-triazole analogs” (Frontiers in Chemistry, 2022, IF: 4.873)